Cargando…

Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis

BACKGROUND/AIMS: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seung Kak, Yim, Hyung Joon, Kim, Jeong Han, Lee, Chan Uk, Yeon, Jong Eun, Suh, Sang Jun, Jung, Young Kul, Kim, Yun Soo, Kim, Ju Hyun, Kwon, Oh Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129658/ https://www.ncbi.nlm.nih.gov/pubmed/33115966 http://dx.doi.org/10.5009/gnl20074

Ejemplares similares

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
por: Lee, Han Ah, et al.
Publicado: (2016)

Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response
por: Kwon, Dae Hun, et al.
Publicado: (2013)

Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir
por: Jo, Yu Jung, et al.
Publicado: (2015)

Is increasing the dose of Entecavir effective in partial virological responders?
por: Erturk, Ayse, et al.
Publicado: (2014)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
por: Choi, Han Na, et al.
Publicado: (2015)

Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
por: Kim, Young Woon, et al.
Publicado: (2015)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
por: Lee, Ji Hun, et al.
Publicado: (2022)

Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
por: Kim, Tae Hyung, et al.
Publicado: (2023)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
por: Song, Joon Chang, et al.
Publicado: (2011)

Reversal of liver cirrhosis: current evidence and expectations
por: Jung, Young Kul, et al.
Publicado: (2017)

Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis
por: Jwa, Hye Young, et al.
Publicado: (2016)

Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis
por: Gu, Dae Hoe, et al.
Publicado: (2018)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Genetic polymorphism at codon 10 of the transforming growth factor-β1 gene in patients with alcoholic liver cirrhosis
por: Lee, Jong Joon, et al.
Publicado: (2011)

Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
por: Park, Jihye, et al.
Publicado: (2017)

The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean
por: Kim, Ju Seung, et al.
Publicado: (2013)

Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study
por: Kwon, Oh Sang, et al.
Publicado: (2010)

Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
por: Kim, Tae Suk, et al.
Publicado: (2017)

Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis
por: Lee, Han Ah, et al.
Publicado: (2022)

Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Ahn, Young Eun, et al.
Publicado: (2021)

Comparison on the Efficacy between Partially Covered Self-Expandable Metal Stent with Funnel-Shaped Enlarged Head versus Uncovered Self-Expandable Metal Stent for Palliation of Gastric Outlet Obstruction
por: Choe, Jung Wan, et al.
Publicado: (2018)

Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach
por: Park, Sang Jung, et al.
Publicado: (2016)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Clinical Significance of Combined Epithelial–Mesenchymal Transition Markers Expression and Role of Rac1 in Hepatocellular Carcinoma
por: Shin, Seung Kak, et al.
Publicado: (2023)

Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis
por: Lee, Han Ah, et al.
Publicado: (2021)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article
por: Shin, Seung Kak, et al.
Publicado: (2017)

Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
por: Lee, Yoonseok, et al.
Publicado: (2023)

Characteristics of contrast-enhanced ultrasound in distinguishing small (≤3 cm) hepatocellular carcinoma from intrahepatic cholangiocarcinoma
por: Shin, Seung Kak, et al.
Publicado: (2018)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores
por: Kim, Tae Hyung, et al.
Publicado: (2020)

Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial
por: Cho, Eun Ju, et al.
Publicado: (2018)

Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma
por: Lee, Han Ah, et al.
Publicado: (2021)

Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Reply
por: Yim, Hyung Joon, et al.
Publicado: (2023)

Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP
por: Lee, Young-Sun, et al.
Publicado: (2020)

Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis
por: Tarao, Kazuo, et al.
Publicado: (2021)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
por: Jun, Dae Won, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vqujbf4cvc6io9ni6fsqel6lpa